Literature DB >> 17200345

Clonal and parallel evolution of primary lung cancers and their metastases revealed by molecular dissection of cancer cells.

Kenji Takahashi1, Takashi Kohno, Shingo Matsumoto, Yukihiro Nakanishi, Yasuhito Arai, Seiichiro Yamamoto, Toshiyoshi Fujiwara, Noriaki Tanaka, Jun Yokota.   

Abstract

PURPOSE: Several models of cancer progression, including clonal evolution, parallel evolution, and same-gene models, have been proposed to date. The purpose of this study is to investigate the authenticity of these models by comparison of accumulated genetic alterations between primary and corresponding metastatic lung cancers. EXPERIMENTAL
DESIGN: A whole-genome allelic imbalance scanning using a high-resolution single nucleotide polymorphism array and mutational analysis of the p53, EGFR, and KRAS genes were done on eight sets of primary and metastatic lung cancers. Based on the genotype data, the natural history of each case was deduced, and candidate metastasis suppressor loci were determined.
RESULTS: Five to 20 chromosomal regions showed allelic imbalance in each tumor. Accumulated genetic alterations were similar between primary and corresponding metastatic tumors, and the majority(>67%) of genetic alterations detected in metastatic tumors was also detected in the corresponding primary tumors. On the other hand, in seven of the eight cases, there were genetic alterations accumulated only in metastatic tumors. Among these alterations, allelic imbalances at chromosome 11p15 and 11p11-p13 regions were the most frequent ones (4 of 8, 50%). Likewise, four cases showed genetic alterations detected only in primary tumors.
CONCLUSIONS: The natural history of each case indicated that the process of metastasis varies among cases, and that all three models are applicable to lung cancer progression. According to the clonal and parallel evolution models, it is possible that a metastasis suppressor gene(s) for lung cancer is present on chromosome 11p.

Entities:  

Mesh:

Year:  2007        PMID: 17200345     DOI: 10.1158/1078-0432.CCR-06-0659

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  16 in total

Review 1.  Molecular determinants of lung cancer metastasis to the central nervous system.

Authors:  Timothy G Whitsett; Landon J Inge; Harshil D Dhruv; Philip Y Cheung; Glen J Weiss; Ross M Bremner; Jeffrey A Winkles; Nhan L Tran
Journal:  Transl Lung Cancer Res       Date:  2013-08

Review 2.  A systems biology approach to defining metastatic biomarkers and signaling pathways.

Authors:  Natalie E Goldberger; Kent W Hunter
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2009 Jul-Aug

3.  Expression and clinical significance of genes frequently mutated in small cell lung cancers defined by whole exome/RNA sequencing.

Authors:  Reika Iwakawa; Takashi Kohno; Yasushi Totoki; Tatsuhiro Shibata; Katsuya Tsuchihara; Sachiyo Mimaki; Koji Tsuta; Yoshitaka Narita; Ryo Nishikawa; Masayuki Noguchi; Curtis C Harris; Ana I Robles; Rui Yamaguchi; Seiya Imoto; Satoru Miyano; Hirohiko Totsuka; Teruhiko Yoshida; Jun Yokota
Journal:  Carcinogenesis       Date:  2015-04-11       Impact factor: 4.944

4.  Biological resonance for cancer metastasis, a new hypothesis based on comparisons between primary cancers and metastases.

Authors:  Dongwei Gao; Sha Li
Journal:  Cancer Microenviron       Date:  2013-11-10

5.  A comparison on expression of selected biomarkers between primary lung cancers and matched metastases.

Authors:  Dongwei Gao; Tiehong Zhang; Sha Li; Qi Liu; Jiajun Du
Journal:  Med Oncol       Date:  2013-10-08       Impact factor: 3.064

6.  Genomic rearrangements define lineage relationships between adjacent lepidic and invasive components in lung adenocarcinoma.

Authors:  Stephen J Murphy; Dennis A Wigle; Joema Felipe Lima; Faye R Harris; Sarah H Johnson; Geoffrey Halling; Michael K Asiedu; Charlie T Seto; Simone Terra; Farhad Kosari; Tobias Peikert; Ping Yang; Marie-Christine Aubry; George Vasmatzis
Journal:  Cancer Res       Date:  2014-06-01       Impact factor: 12.701

7.  TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib.

Authors:  Kung-Chu Ho; Yu-Hua Dean Fang; Hsiao-Wen Chung; Yuan-Chang Liu; John Wen-Cheng Chang; Ming-Mo Hou; Cheng-Ta Yang; Nai-Ming Cheng; Tzu-Pei Su; Tzu-Chen Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-03       Impact factor: 9.236

8.  Phenotype of bone metastases of non-small cell lung cancer: epidermal growth factor receptor expression and K-RAS mutational status.

Authors:  Gayane Badalian; Tamás Barbai; Erzsébet Rásó; Katalin Derecskei; Miklós Szendrôi; József Tímár
Journal:  Pathol Oncol Res       Date:  2007-07-03       Impact factor: 3.201

Review 9.  Occurrence of cancer at multiple sites: towards distinguishing multigenesis from metastasis.

Authors:  Wei-Kang Zhang; Chun Zhang; Jing J Zhang; Shi V Liu
Journal:  Biol Direct       Date:  2008-04-11       Impact factor: 4.540

Review 10.  Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review.

Authors:  James Sherwood; Simon Dearden; Marianne Ratcliffe; Jill Walker
Journal:  J Exp Clin Cancer Res       Date:  2015-09-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.